Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business

Dr Reddy's launches oral semaglutide biosimilar Obeda in India

New Delhi: Dr Reddy's Laboratories Ltd on Wednesday announced the launch of its oral semaglutide biosimilar, indicated for Type 2 diabetes mellitus, in India under the Obeda brand.

This launch follows Dr Reddy's recent generic semaglutide injection launches in India and Canada, Dr Reddy's Laboratories Ltd (DRL) said in a statement.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.